NAYZILAM® (midazolam) nasal spray, CIV, gets extended shelf life approval

The U.S. Food and Drug Administration has reviewed new drug stability data from UCB, Inc. and approved an extended shelf life from 12 to 24 months for NAYZILAM — the first nasal spray approved for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 12 years of age and older.

Patients and caregivers prescribed NAYZILAM will now receive a product that reflects the extended expiration date of up to 24 months.

 

 

Learn More: Healthcare Professionals | NAYZILAM® (midazolam) nasal spray, CIV

Related Posts

SOAR Webinar

SOAR Webinar

**At this time, the SOAR study has reached capacity for conference participation. However, there still may be opportunities for research participation at the family conference due to cancellations or addition of other opportunities. If you would like to be placed on a...

FDA Issues Recall On Clonazepam Orally Disintegrating Tablets

FDA Issues Recall On Clonazepam Orally Disintegrating Tablets

The Dup15q Alliance is aware of the recent release by the FDA regarding Clonazepam Orally Disintegrating Tablets USP by Endo USA due to potential product carton strength mislabeling. Ongoing investigation identified the possibility that the affected clonazepam product...

Recall – Vigabatrin for Oral Solution USP

Recall – Vigabatrin for Oral Solution USP

TOPIC: Vigabatrin for Oral Solution USP, 500 mg by InvaGen Pharmaceuticals: Recall - Due to Leaking Sachets AUDIENCE: Patient, Health Professional, Pharmacy, Pediatric, Neurology ISSUE: InvaGen Pharmaceuticals is recalling one lot, NB301030, of Vigabatrin for Oral...